$180,000
LEIDOS BIOMEDICAL RESEARCH, INC.
Maryland
National Cancer Institute (NCI)
In light of the emergence of the novel coronavirus, SARS-CoV-2, and the urgent need to mitigate the pathogen’s spread. There is a crucial need for accurate laboratory-based methods for initial diagnosis, asymptomatic carriage and overall public health understanding of the extent of this disease. The current lack of validated and widely available standardized tests, procedures and reagents for assessment of SARS-CoV-2-specific antibody responses is a critical gap in the rapid response to the SARS-CoV-2 pandemic. a major goal and focus of SeroNet is determining the molecular and cellular components of the immune response to SARS-CoV-2 to understand the innate, humoral and adaptive response, as well as to understand barriers to access